NCT01870388

A Pharmacokinetic Study of Baricitinib in Participants With Liver Disease

A Pharmacokinetic Study of Baricitinib in Subjects With Hepatic Dysfunction

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Accepted

Summary

The main purpose of this study is to measure how much of the study drug called baricitinib gets into the blood stream and how long it takes the body to get rid of it. Healthy participants and those with liver disease may enroll. The study will last about 7 days for each participant, not including screening.

Conditions

• Liver Diseases
• Hepatic Insufficiency

Interventions

Type	Name	Description
DRUG	Baricitinib	Administered orally

Timeline

• Start date: 2013-06-01
• Primary completion: 2013-07-01
• Completion: 2013-07-01
• First posted: 2013-06-06
• Last updated: 2017-06-06
• Results posted: 2017-04-21

Locations

2 sites across 1 country: United States